

September 5, 2012



TONIX Pharmaceuticals to Present at Rodman & Renshaw 14th Annual Global Investment Conference on September 11

CEO to Highlight Company's New Drug Candidate Targeting Fibromyalgia by Increasing Restorative Sleep

NEW YORK, NY -- (MARKETWIRE) -- 09/05/12 -- Tonix Pharmaceuticals Holding Corp. (OTCQB: TNXP) ("TONIX" or the "Company"), a specialty pharmaceutical company developing a non-addictive treatment, sublingual TNX-102, for fibromyalgia ("FM") and post-traumatic stress disorder ("PTSD"), today announced that Seth Lederman, M.D., Chief Executive Officer of TONIX, will present a corporate overview at the Rodman & Renshaw 14th Annual Global Investment Conference on Tuesday, September 11, 2012. Dr. Lederman is scheduled to present at 9:35 am ET in the North Foyer room. The event will be held September 9 through 11 at The Waldorf-Astoria hotel in New York City.

A live webcast of the TONIX presentation may be accessed at <http://www.wsw.com/webcast/rrshq22/tnxp> or on the Company's website at www.tonixpharma.com. The webcast will be archived for 90 days following the presentation.

Information about the conference is available at www.rodman.com.

About TNX-102 SL

TNX-102 SL is a novel sublingual formulation of cyclobenzaprine for bedtime use. TONIX designed TNX-102 SL to provide faster and more efficient absorption of cyclobenzaprine, relative to currently marketed products approved for other indications. TONIX believes TNX-102 SL administered at bedtime will provide more targeted sleep quality effects with less likelihood of side effects than commercially-available cyclobenzaprine preparations.

About TONIX

TONIX is developing innovative prescription medications for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX's core technology improves the quality of sleep in patients with chronic pain syndromes. TONIX's lead product is designed to be a fundamental advance in sleep hygiene and pain management and to be safer and more effective than currently available treatments. Its most advanced product candidate, sublingual TNX-102 for fibromyalgia and PTSD, is a novel dosage formulation of cyclobenzaprine, the active ingredient in two U.S. FDA-approved muscle relaxants. To learn more about the Company

and its pipeline, please visit www.tonixpharma.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on TONIX's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. TONIX does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on March 30, 2012 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

Contacts:

Tonix Pharmaceuticals Holding Corp.

Benjamin Selzer
Chief Operating Officer
(212) 980-9155 x106

[Email Contact](#)

LHA

Anne Marie Fields
(212) 838-3777

[Email Contact](#)

or

Bruce Voss
(310) 691-7100

[Email Contact](#)